Paclitaxel is a powerful anticancer (chemotherapy) drug originally derived from the bark of the Pacific yew tree (Taxus brevifolia). It belongs to the taxane class of chemotherapeutic agents and is widely used in the treatment of several cancers, including:
∙ Breast cancer
∙ Ovarian cancer
∙ Non-small cell lung cancer (NSCLC)
∙ Kaposi’s sarcoma (particularly in patients with AIDS)
Paclitaxel works by stabilizing microtubules in cells, preventing their normal breakdown during cell division. This leads to mitotic arrest and apoptosis (cell death) in rapidly dividing cancer cells.
It is typically administered intravenously, and dosing schedules vary depending on the type and stage of cancer being treated.
Parent: Paclitaxel
Parent: Paclitaxel
Parent: Paclitaxel
Parent: Paclitaxel
Parent: Paclitaxel
Parent: Paclitaxel
Parent: Paclitaxel
Due to its complex structure and natural origins, paclitaxel is susceptible to synthetic and degradation impurities, which must be carefully controlled according to ICH Q3A/B and regulatory guidelines for safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Paclitaxel is used to treat a variety of cancers, including:
Common side effects include:
Mouth sores and fatigue